Kymr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kymr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kymr Today - Breaking & Trending Today

Oppenheimer Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00

Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lowered by Oppenheimer from $53.00 to $52.00 in a research report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. increased their price […] ....

Jared Gollob , Stifel Nicolaus , Piper Sandler , Jeffreyw Albers , China Universal Asset Management Co , Allspring Global Investments Holdings , Jpmorgan Chase Co , Wolfe Research , Securities Exchange Commission , Exchange Traded Concepts , Quest Partners , Kymera Therapeutics Inc , Kymera Therapeutics , Free Report , Truist Financial , Moderate Buy , Get Free Report , Exchange Commission , Director Jeffrey , Global Investments Holdings , Universal Asset Management , Traded Concepts , Aigen Investment Management , Kymera Therapeutics Daily , Nasdaq Kymr , Lower Price Target ,

Kymera Therapeutics (NASDAQ:KYMR) Issues Earnings Results, Beats Expectations By $0.04 EPS

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return […] ....

Piper Sandler , Securities Exchange Commission , Wolfe Research , Kymera Therapeutics Company Profile , Venture Fund Xlp Atlas , Jpmorgan Chase Co , Kymera Therapeutics Inc , Kymera Therapeutics , Get Free Report , Director Bruce Booth , Exchange Commission , Venture Fund , Truist Financial , Kymera Therapeutics Daily , Nasdaq Kymr ,

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target […] ....

United States , Piper Sandler , Stifel Nicolaus , Jared Gollob , Venture Fund Xlp Atlas , Td Asset Management Inc , Harbor Capital Advisors Inc , Raymond James Associates , Kymera Therapeutics Company Profile , Kymera Therapeutics Inc , Wolfe Research , Allspring Global Investments Holdings , Kymera Therapeutics , Get Free Report , Venture Fund , Capital Advisors , Management Inc , Global Investments Holdings , Arizona State Retirement System , Get Free , Kymera Therapeutics Daily , Nasdaq Kymr ,

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective […] ....

United States , Piper Sandler , Stifel Nicolaus , Quest Partners , Kymera Therapeutics Company Profile , China Universal Asset Management Co , Jpmorgan Chase Co , Venture Fund Xlp Atlas , Hsbc Holdings , Securities Exchange Commission , Allspring Global Investments Holdings , Kymera Therapeutics Inc , Kymera Therapeutics , Get Free Report , Venture Fund , Exchange Commission , Director Bruce Booth , Global Investments Holdings , State Retirement System , Universal Asset Management , Get Free , Kymera Therapeutics Daily , Nasdaq Kymr ,

Kymera Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.79) Per Share (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 EPS estimates for Kymera Therapeutics in a research note issued to investors on Friday, February 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.79) for the quarter. The consensus […] ....

Jeffreyw Albers , Stifel Nicolaus , Piper Sandler , Jared Gollob , Blackrock Inc , Kymera Therapeutics Company Profile , Morgan Stanley , Kymera Therapeutics Inc , Metlife Investment Management , Dimensional Fund Advisors , Securities Exchange Commission , Wells Fargo Company , York Mellon Corp , Kymera Therapeutics , Free Report , Kymera Therapeutic , Get Free Report , Wells Fargo , Director Jeffrey , Exchange Commission , New York Mellon Corp , Life Investment Management , Fund Advisors , Kymera Therapeutics Daily , Nasdaq Kymr , Earnings Estimates ,